Johan L. J. Verbeeck,
VP, Business Development, Immunology
Johan Verbeeck is Vice President, Business Development, Immunology for Johnson & Johnson Innovation, Janssen Business Development. In this role, Johan leads all business development activities for this therapeutic focus area and has accountability for Immunology transactions, acquisitions, scientific licensing and alliance management.
Prior to his current position, Johan was Senior Director, Licensing, Immunology and External Partnering, where he was involved in the identification and evaluation of multiple opportunities and, most recently, the successful completion of the partnership with Protagonist Therapeutics for its oral IL-23 inhibitor for Inflammatory Bowel Disease.
Johan joined Johnson & Johnson in 1996, through Janssen Pharmaceutica in Belgium, in the Department of Animal Health and subsequently worked in Toxicology, where he became a Study Director for a multitude of small molecule development projects. In 2005, Johan joined Tibotec, as Lead Toxicologist for the development of Prezista® and Intelence®, the company’s first two approved anti-HIV drugs. At the same time, he was Preclinical Development Leader for bedaquiline, the first new drug in development for tuberculosis in over 40 years. For the latter program, he received the Johnson & Johnson Medal for Research and Development in 2013. In 2007, after the approval of Intelence, Johan became Head of Toxicology Sciences for Janssen Research & Development. He also served as Alliance Manager in the External Alliances and Business Models group.
Prior to joining the Janssen Business Development team, Johan joined the London Innovation Center in 2013 as one of its first members and played an active role in helping to establish the center, building its European network and securing several transactions.
Johan holds a Doctorate in Veterinary Medicine from the University of Gent, Belgium. He also graduated Cum Laude with a Master of Science in Applied Toxicology from the University of Surrey, United Kingdom.